Woodline Partners LP Has $12.60 Million Stake in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Woodline Partners LP increased its stake in Amneal Pharmaceuticals by 165.2%, acquiring a total of 1,504,095 shares, which amounts to approximately $12.6 million as of the latest SEC filing.
• A variety of hedge funds have also shown interest in Amneal Pharmaceuticals, with GAMMA Investing LLC increasing its position by an extraordinary 5,975.0% during the same period.
• Amneal Pharmaceuticals has received a buy rating from The Goldman Sachs Group and has a consensus target price of $11.60, reflecting positive analyst sentiment despite recent insider selling activity.

Woodline Partners LP boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 165.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,504,095 shares of the company's stock after purchasing an additional 937,035 shares during the period. Woodline Partners LP owned about 0.49% of Amneal Pharmaceuticals worth $12,604,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AMRX. Nuveen LLC bought a new position in shares of Amneal Pharmaceuticals during the 1st quarter worth approximately $19,581,000. Vanguard Group Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 6.2% during the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock valued at $132,092,000 after acquiring an additional 920,758 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at $5,733,000. Walleye Capital LLC grew its holdings in shares of Amneal Pharmaceuticals by 1,333.7% in the 1st quarter. Walleye Capital LLC now owns 558,842 shares of the company's stock worth $4,683,000 after purchasing an additional 519,863 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Amneal Pharmaceuticals by 32.6% during the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock worth $17,492,000 after purchasing an additional 512,842 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded down $0.21 during trading hours on Monday, reaching $9.79. 1,377,949 shares of the company were exchanged, compared to its average volume of 1,673,730. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $10.34. The stock's fifty day moving average is $8.83 and its two-hundred day moving average is $8.19. The company has a market cap of $3.07 billion, a price-to-earnings ratio of 979.98 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group began coverage on shares of Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $11.60.

Insider Transactions at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 6,340 shares of the business's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $9.50, for a total transaction of $60,230.00. Following the completion of the sale, the executive vice president directly owned 146,403 shares of the company's stock, valued at $1,390,828.50. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Andrew S. Boyer sold 279,244 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the transaction, the executive vice president directly owned 152,426 shares in the company, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 609,206 shares of company stock valued at $5,700,625 in the last three months. Company insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.